Procalcitonin-guided antibiotic therapy: A potentially effective and efficient strategy

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 4, 2015, Pages 519-520

  Plebani, Mario ^a   Fabbri, Leonardo M ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT; CALCITONIN; PROTEIN PRECURSOR;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; EDITORIAL; HORMONE BLOOD LEVEL; HUMAN; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; PRIORITY JOURNAL; TREATMENT FAILURE; BLOOD; BLOOD ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; RESPIRATORY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BLOOD CHEMICAL ANALYSIS; CALCITONIN; DELIVERY OF HEALTH CARE; HUMANS; PROTEIN PRECURSORS; RESPIRATORY TRACT INFECTIONS;

EID: 84925830361     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0061     Document Type: Editorial

References (11)

1. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77.
2. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7.
3. Hudson LL, Woods CW, Ginsburg GS. A novel diagnostic approach may reduce inappropriate antibiotic use for acute respiratory infections. Expert Rev Anti Infect Ther 2014;12:279-82.
4. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168:2000-7.
5. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: a rand omized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9-19.
6. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9:CD007498.
7. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74.
8. Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, et al. Antibiotic treatment of severe exacerbations ofchronic obstructive pulmonary disease with procalcitonin: a randomized non inferiority trial. PLOS One 2015 (in press).
9. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalci-tonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792-9.
10. Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29:579-86.
11. Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015;53:583-92.